Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
The debate on CBD has seemed to lessen with both sides
agreeing that this chemical compound derived from marijuana has a myriad of
benefits. The fact...
In recent years, scientific studies have shown us that human bodies have an ECS system (endocannabinoid system). The ECS system is important for helping...